Challenge/Limitation	What will be done to minimise/mitigate effect
Loss-to-follow-up	Inclusion of survey testing, primary care and Second
Some infections and symptoms may be missed where	Generation Survey learning, primary care and Second
participants are not surveyed at a given study round	chances of identifying all active infections
	<ul> <li>Inclusion of antibody data to identify infections not</li> </ul>
	identified through testing for active infection
Surveys may not adequately conture associated marhidity	Triangulation of long term offset of SARS CoV 2
Sumptom list is not exhaustive, and sumptoms do not have an	• Thangulation of long-term effect of SARS-Cov-2
symptom list is not exhaustive, and symptoms do not have an	Successible for the sources
	• Survey list for both SIS and Colvins includes those
Fuching motions of the man domin	symptoms considered most narmiul in PP1 work(1)
Evolving nature of the pandemic	• It is importance to understand the past dynamics of
SIS and Colvining are historic studies that took place when	SARS-Cov-2
ine who-type and dena-type SARS-Cov-2 variants were	• The health effects of earlier variants continue to be felt
Misalassification bios	A Turbuing of summer to the transmission of
Asymptometic infections may be loss likely to be identified	• Inclusion of survey testing to increase the chances of
Asymptomatic infections may be less likely to be identified	identifying all active infections
than symptomatic infections (outside of testing done through	• Inclusion of antibody data to identify asymptomatic
the surveys) as a consequence of government testing strategy,	infections/infections not identified through testing for
potentially leading to either an under- or overestimation of	active infection
Selection bios	• A division of offs to the former is t
Those at risk of developing long COVID (a.g. potentially	Adjustment of effect estimates for covariates
those with symptometic agute SAPS CoV 2 infection or	• Subgroup analyses by participant demographic and
those with symptomatic acute SARS-Cov-2 infection, of	
to participate in the surveys	• Inclusion of antibody data to identify asymptomatic
to participate in the surveys	infections/infections not identified through testing for
	active infection
Response bias	• Inclusion of antibody data to identify those with an
Participants with SARS-CoV-2 infection may overreport	unrecognised SARS-CoV-2 infection
symptoms. Survey participants are not presented with	• Triangulation of long-term effect of SARS-CoV-2
symptom definitions in either CoMMinS or SIS	infection from multiple sources
Inadequate study power	• Use of two different cohorts to investigate associations
Outcome categories may be too broad and/or numbers too	• Combining outcomes may conversely increase the power
small to detect associations	to detect an association
Chance associations	• ICD-10 and BNFC chapters selection informed by
At (e.g.) the 5% level (i.e., using $p < 0.05$ as a cut-off which is	clinical consultation, documented symptomatic SARS-
a less than 5% chance that the null hypothesis of no	COV-2 in children, how well they are reported, and PPI
association is false), 1 in 20 associations investigated will be	work
statistically-significant purely on the basis of chance	• Evidence across multiple outcome types will help
	determine plausibility of associations (e.g., comparing
	associations across relevant related survey symptoms,
	diagnoses and prescriptions for a given condition)
Missing data	• Use of both research data and EHR data to inform
Missing data on socio-demographic and clinical covariates	covariates
may bias, or reduce the power to detect, effect estimates, if	• Exploration of patterns in missing data and use of
missing data are not random (i.e., more likely for certain	multiple imputation where appropriate
covariate categories) and confound/modify the association	
between exposure and outcome	
Incomplete outcome reporting in EHRs	• Association of SARS-CoV-2 infection with multiple
Not all outcomes recorded due to incomplete or variable	different types of outcomes investigated to increase
recording by nearmare professionals, and individuals not	likelihood of capturing effect of infection on long-term
presenting to nearthcare services	health outcomes
Use of data on recent symptoms as a proxy for persistent	• The assumption that repeated symptoms correlate with
symptoms	persistent symptoms is not necessarily an issue if long-
A symptom being reported as experienced in multiple survey	COVID symptoms are fluctuating
the whole time. SIS and CoMMinS do got define (access)	• Persistent symptoms will be analysed in two ways for
use whole time. Sis and Colviving do not define 'recent'	SIS, with use of data collected specifically on persistent
symptoms in the same way	symptoms as well as repeated data collection on recent
	symptoms
Uutcomes due to other causes	• Use of a control/unexposed group
I ne outcomes investigated (symptoms, school absences due to	• We are utilising all available data, and comparing hazard
niness, diagnoses of conditions, medication use and health	ratios for time since SARS-CoV-2 diagnosis, with follow
service attendance) have multiple other potential	up without or before infection for each outcome
causes/explanations	<ul> <li>Adjustment of effect estimates for covariates</li> </ul>

	Sensitivity analyses
Differential clinical course in different individuals	• Use of broad chapters of diagnoses and prescriptions to
The long-term effects of SARS-CoV-2 infection may be seen	more fully capture all possible long-term effects of
in different CYP in different ways	SARS-CoV-2 infection
	Clustering and latent class analyses planned